{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Product+B&page=2", "query": { "intervention": "Product B", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Product+B&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-23T06:55:21.631Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02099240", "title": "Patients Response to Early Switch To Oral:Osteomyelitis Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Osteomyelitis" ], "interventions": [ { "name": "oral antibiotics", "type": "DRUG" }, { "name": "intravenous antibiotics", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Julio Ramirez", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 11, "start_date": "2014-03-06", "completion_date": "2018-11-07", "has_results": false, "last_update_posted_date": "2021-04-06", "last_synced_at": "2026-09-23T06:55:21.631Z", "location_count": 1, "location_summary": "Louisville, Kentucky", "locations": [ { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02099240" }, { "nct_id": "NCT07248839", "title": "A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers", "Hepatic Impairment" ], "interventions": [ { "name": "BMS-986435", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 69, "start_date": "2025-12-15", "completion_date": "2026-08-20", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-09-23T06:55:21.631Z", "location_count": 3, "location_summary": "Chandler, Arizona • Miami Lakes, Florida • San Antonio, Texas", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07248839" }, { "nct_id": "NCT07322263", "title": "Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Non-Muscle Invasive Bladder Cancer (NMIBC)", "Urothelial Carcinoma", "Carcinoma in Situ (CIS)", "High-Grade Papillary Bladder Tumors", "BCG-Unresponsive Bladder Cancer", "Ta Stage Bladder Cancer", "T1 Stage Bladder Cancer", "BCG-Refractory Bladder Cancer", "High-Risk NMIBC", "Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)" ], "interventions": [ { "name": "Intravesical Gemcitabine and Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael A. O'Donnell", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 174, "start_date": "2026-04-10", "completion_date": "2033-01-01", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-09-23T06:55:21.631Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT07322263" }, { "nct_id": "NCT06757634", "title": "Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Arm A: Gedatolisib + Palbociclib + Fulvestrant", "type": "DRUG" }, { "name": "Arm B: Ribociclib + Fulvestrant", "type": "DRUG" }, { "name": "Arm C: Gedatolisib + Palbociclib + Letrozole", "type": "DRUG" }, { "name": "Arm D: Ribociclib + Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celcuity Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1180, "start_date": "2025-07-24", "completion_date": "2033-07-30", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-09-23T06:55:21.631Z", "location_count": 22, "location_summary": "Duarte, California • Fullerton, California • Los Angeles, California + 19 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Plantation", "state": "Florida" }, { "city": "Tamarac", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06757634" }, { "nct_id": "NCT01125553", "title": "A Comparison Between Two Formulations of NN5401 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes", "Healthy" ], "interventions": [ { "name": "insulin degludec/insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 26, "start_date": "2010-05", "completion_date": "2010-08", "has_results": false, "last_update_posted_date": "2015-09-25", "last_synced_at": "2026-09-23T06:55:21.631Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01125553" }, { "nct_id": "NCT00509301", "title": "Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Glioblastoma Multiforme" ], "interventions": [ { "name": "131-I-chTNT-1/B MAB", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Peregrine Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2006-11", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2011-08-05", "last_synced_at": "2026-09-23T06:55:21.631Z", "location_count": 4, "location_summary": "Phoenix, Arizona • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00509301" }, { "nct_id": "NCT07109219", "title": "Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia (B-ALL)" ], "interventions": [ { "name": "AZD4512 monotherapy", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 83, "start_date": "2025-11-12", "completion_date": "2028-07-03", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-23T06:55:21.631Z", "location_count": 6, "location_summary": "Duarte, California • Jacksonville, Florida • Chicago, Illinois + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Franklin", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07109219" }, { "nct_id": "NCT02756611", "title": "A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 258, "start_date": "2016-06-22", "completion_date": "2022-03-11", "has_results": true, "last_update_posted_date": "2023-04-10", "last_synced_at": "2026-09-23T06:55:21.631Z", "location_count": 6, "location_summary": "Louisville, Kentucky • Baltimore, Maryland • Hackensack, New Jersey + 3 more", "locations": [ { "city": "Louisville", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02756611" }, { "nct_id": "NCT05025800", "title": "ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Aggressive B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage III Grade 2 Follicular Lymphoma", "Ann Arbor Stage III Grade 3 Follicular Lymphoma", "Ann Arbor Stage III Marginal Zone Lymphoma", "Ann Arbor Stage IV Grade 1 Follicular Lymphoma", "Ann Arbor Stage IV Grade 2 Follicular Lymphoma", "Ann Arbor Stage IV Grade 3 Follicular Lymphoma", "Ann Arbor Stage IV Marginal Zone Lymphoma", "Composite Lymphoma", "Indolent B-Cell Non-Hodgkin Lymphoma", "Refractory Aggressive B-Cell Non-Hodgkin Lymphoma", "Refractory Follicular Lymphoma", "Refractory Grade 3b Follicular Lymphoma", "Refractory High Grade B-Cell Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Marginal Zone Lymphoma", "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma", "Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma", "Richter Syndrome" ], "interventions": [ { "name": "CD47 Antagonist ALX148", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2021-10-13", "completion_date": "2028-03-21", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-09-23T06:55:21.631Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05025800" }, { "nct_id": "NCT05585307", "title": "Study of Novel Antiretrovirals in Participants With HIV-1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Bavtavirine", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" }, { "name": "Standard of Care (Substudy 01)", "type": "DRUG" }, { "name": "GS-1720", "type": "DRUG" }, { "name": "Standard of Care (Substudy 02)", "type": "DRUG" }, { "name": "GS-6212", "type": "DRUG" }, { "name": "Standard of Care (Substudy 03)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 49, "start_date": "2022-10-26", "completion_date": "2024-03-18", "has_results": true, "last_update_posted_date": "2025-05-08", "last_synced_at": "2026-09-23T06:55:21.631Z", "location_count": 38, "location_summary": "Long Beach, California • Los Angeles, California • San Francisco, California + 14 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05585307" } ] }